Zacks Investment Research·Jun 30, 2026
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's WhyThe latest trading day saw Humacyte, Inc. (HUMA) settling at $0.78, representing a -2.32% change from its previous close.
Humacyte, Inc.(HUMA)Earnings, Financials & Key Ratios
HUMA•NASDAQ
$0.77
Price updated Jul 7, 2026
AboutHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Show more
- Revenue$2M
- EBITDA-$100M+6.6%
- Net Income-$41M+72.5%
- EPS (Diluted)-0.26+79.4%
- Gross Margin-736.46%
- EBITDA Margin-4911.29%
- Operating Margin-5271.69%
- Net Margin-2003.58%
- ROE-1313.38%
HUMA Price & Volume
Humacyte, Inc. (HUMA) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Challenges Regenerative Growth Trajectory
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Regulatory and financing dependency
Key Thesis Takeaways
- Humacyte remains in a high-risk, pre-commercial phase characterized by significant capital intensity and reliance on external financing to support its proprietary LURE manufacturing system.
- While the company pursues regulatory milestones for its Human Acellular Vessel, the lack of a repeatable revenue model and persistent operating losses exceeding $25 million per quarter create substantial uncertainty.
- Investors should monitor the company's ability to achieve economies of scale, as current financial structures suggest continued vulnerability to dilutive capital raises.
Verdict Logic
the company's reliance on external financing to cover quarterly operating losses often exceeding $25 million suggests significant liquidity risk and potential for further shareholder dilution.
HUMA Growth Metrics
Humacyte, Inc. (HUMA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years6.45%
3 Years9.2%
TTM-73.97%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-25.65%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM14.64%
Return on Capital
10 Years-64.83%
5 Years-69.7%
3 Years-89.31%
Last Year-99.52%
HUMA Recent Earnings
Humacyte, Inc. (HUMA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 2/12 qtrs (29%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.09+10.0%
$0.10
Rev
$495,000-66.2%
$1M
Q2 2026
Mar 27, 2026Metric
Actual
Est
EPS
$0.13+0.0%
$0.13
Rev
$467,000-65.4%
$1M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.14+17.6%
$0.17
Rev
$753,000-44.2%
$1M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.24-60.0%
$0.15
Rev
$301,000-67.2%
$917,830
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.09vs $0.10+10.0% | $495,000vs $1M-66.2% |
| Q2 2026 | Mar 27, 2026 | $0.13vs $0.13+0.0% | $467,000vs $1M-65.4% |
| Q4 2025 | Nov 12, 2025 | $0.14vs $0.17+17.6% | $753,000vs $1M-44.2% |
| Q3 2025 | Aug 11, 2025 | $0.24vs $0.15-60.0% | $301,000vs $917,830-67.2% |
Based on last 12 quarters of dataView full earnings history →
Latest HUMA News
Recent stock market news and headlines for Humacyte, Inc. (HUMA)
Zacks Investment Research·Jun 25, 2026
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader MarketHumacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from its prior day's close.
Zacks Investment Research·Jun 19, 2026
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a BetWhen deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Zacks Investment Research·Jun 16, 2026
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should KnowHumacyte, Inc. (HUMA) closed the most recent trading day at $1.03, moving 3.74% from the previous trading session.
Seeking Alpha·Jun 15, 2026
Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access TranscriptHumacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript
Peers Comparison
Key metrics vs top competitors for Humacyte, Inc. (HUMA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.77 | $129.51M | -2.97 | — | -2003.58% | -1313.38% | — | |
| $0.72 | $32.23M | -0.87 | 15.84% | -49.3% | -1344.47% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $32.80 | $1.66B | -136.67 | 14.88% | -0.83% | -0.95% | — | |
| $13.07 | $540.04M | -15.75 | -3.76% | -10% | -17.65% | — | |
| $24.46 | $1.19B | 116.48 | 13.59% | 2.55% | 2.66% | — |
Compare HUMA vs Peers
Humacyte, Inc. (HUMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HUMA SEC Filings & Documents
Humacyte, Inc. (HUMA) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 8, 2026·SEC
Material company update
Apr 24, 2026·SEC
Material company update
Mar 19, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when HUMA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HUMA Frequently Asked Questions
Humacyte, Inc. (HUMA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Humacyte, Inc.'s revenue?
Humacyte, Inc. (HUMA) reported $2.0M in revenue for fiscal year 2025. This represents a 67% decrease from $6.2M in 2019.
Is HUMA profitable?
Humacyte, Inc. (HUMA) reported a net loss of $97.6M for fiscal year 2025.
Dividend & Returns
What is HUMA's return on equity?
Humacyte, Inc. (HUMA) has a return on equity (ROE) of -1313.4%. Negative ROE indicates the company is unprofitable.
What is Humacyte, Inc.'s free cash flow?
Humacyte, Inc. (HUMA) had negative free cash flow of $102.4M in fiscal year 2025, likely due to heavy capital investments.